This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): Noscapine
Description: CB3304 is an orally active alkaloid derived from opium. Preclinical studies have shown that CB3304 is a microtubule targeting agent that alters microtubule dynamics, blocks mitosis, and causes apoptosis. Preclinical antitumor activity has been demonstrated in a number of tumor types including preclinical models of lymphoma, breast cancer, bladder cancer, melanoma and glioblastoma. CB3304 has also shown the ability to inhibit the proliferation of both paclitaxel sensitive and paclitaxel resistant human ovarian carcinoma cell lines.
Deal Structure: Cougar licensed exclusive worldwide rights to CB3304 from Emory University in March 2004. As consideration for the rights to noscapine and the analogs of noscapine, the Company paid Emory University an initial license fee. In connection with the license agreement, Cougar has agreed to make payments to Emory University, payable upon the achievement of certain clinical and regulatory milestones. Should CB3304 be commercialized, Cougar will be obligated to pay to Emory University an annual royalty based on net sales of the product. In the event that Cougarsublicenses the licensed technology to a third party, Cougar will be obligated to pay royalties to Emory University based on a fixed rate of fees or royalties received from the sublicense.
In May 2009, Johnson & Johnson and Cougar Biotechnology announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer. Under the terms of the agreement, Johnson & Johnson...See full deal structure in Biomedtracker
Additional information available to subscribers only: